Selected research
Market Outlook & Growth Opportunities
Global Non-Opioid Patch Market Outlook and Growth Opportunities 2026
Market perspective
The global Non-Opioid Patch market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.
The North America market for Non-Opioid Patch is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Non-Opioid Patch is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Non-Opioid Patch is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
In China, the Non-Opioid Patch market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Major global companies in the Non-Opioid Patch market include Teva Pharmaceutical Industries Ltd, Johnson and Johnson, Viatris Inc., Sorrento Therapeutics Inc., Purdue Pharma L.P., NEXGEL Advanced Hydrogel Solutions, Hisamitsu Pharmaceutical Co.,Inc., Grunenthal and Endo International plc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
This report provides an overview of the global Non-Opioid Patch market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Non-Opioid Patch and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Non-Opioid Patch sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Non-Opioid Patch market size, projected growth trends, production technologies, key applications, and end-use industries.
Non-Opioid Patch Segment by Company
Teva Pharmaceutical Industries Ltd
Johnson and Johnson
Viatris Inc.
Sorrento Therapeutics Inc.
Purdue Pharma L.P.
NEXGEL Advanced Hydrogel Solutions
Hisamitsu Pharmaceutical Co.,Inc.
Grunenthal
Endo International plc.
Amneal Pharmaceuticals LLC
Non-Opioid Patch Segment by Type
Prescription Medicines
OTC Medicines
Non-Opioid Patch Segment by Application
Hospital Pharmacies
Drug Stores
Online Pharmacies
Non-Opioid Patch Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Non-Opioid Patch status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Non-Opioid Patch market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Non-Opioid Patch significant trends, drivers, influence factors in global and regions.
6. To analyze Non-Opioid Patch competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Non-Opioid Patch market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Non-Opioid Patch and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Non-Opioid Patch.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Non-Opioid Patch market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Non-Opioid Patch industry.
Chapter 3: Detailed analysis of Non-Opioid Patch manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Non-Opioid Patch in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Non-Opioid Patch in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Prescription Medicines
- OTC Medicines
Applications
- Hospital Pharmacies
- Drug Stores
- Online Pharmacies
Companies covered
- Teva Pharmaceutical Industries Ltd
- Johnson and Johnson
- Viatris Inc.
- Sorrento Therapeutics Inc.
- Purdue Pharma L.P.
- NEXGEL Advanced Hydrogel Solutions
- Hisamitsu Pharmaceutical Co.,Inc.
- Grunenthal
- Endo International plc.
- Amneal Pharmaceuticals LLC
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Non-Opioid Patch Sales Value (2021-2032)
- 1.2.2 Global Non-Opioid Patch Sales Volume (2021-2032)
- 1.2.3 Global Non-Opioid Patch Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Non-Opioid Patch Market Dynamics
- 2.1 Non-Opioid Patch Industry Trends
- 2.2 Non-Opioid Patch Industry Drivers
- 2.3 Non-Opioid Patch Industry Opportunities and Challenges
- 2.4 Non-Opioid Patch Industry Restraints
3 Non-Opioid Patch Market by Company
- 3.1 Global Non-Opioid Patch Company Revenue Ranking in 2025
- 3.2 Global Non-Opioid Patch Revenue by Company (2021-2026)
- 3.3 Global Non-Opioid Patch Sales Volume by Company (2021-2026)
- 3.4 Global Non-Opioid Patch Average Price by Company (2021-2026)
- 3.5 Global Non-Opioid Patch Company Ranking (2024-2026)
- 3.6 Global Non-Opioid Patch Company Manufacturing Base and Headquarters
- 3.7 Global Non-Opioid Patch Company Product Type and Application
- 3.8 Global Non-Opioid Patch Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Non-Opioid Patch Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Non-Opioid Patch Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Non-Opioid Patch Market by Type
- 4.1 Non-Opioid Patch Type Introduction
- 4.1.1 Prescription Medicines
- 4.1.2 OTC Medicines
- 4.2 Global Non-Opioid Patch Sales Volume by Type
- 4.2.1 Global Non-Opioid Patch Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Non-Opioid Patch Sales Volume by Type (2021-2032)
- 4.2.3 Global Non-Opioid Patch Sales Volume Share by Type (2021-2032)
- 4.3 Global Non-Opioid Patch Sales Value by Type
- 4.3.1 Global Non-Opioid Patch Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Non-Opioid Patch Sales Value by Type (2021-2032)
- 4.3.3 Global Non-Opioid Patch Sales Value Share by Type (2021-2032)
5 Non-Opioid Patch Market by Application
- 5.1 Non-Opioid Patch Application Introduction
- 5.1.1 Hospital Pharmacies
- 5.1.2 Drug Stores
- 5.1.3 Online Pharmacies
- 5.2 Global Non-Opioid Patch Sales Volume by Application
- 5.2.1 Global Non-Opioid Patch Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Non-Opioid Patch Sales Volume by Application (2021-2032)
- 5.2.3 Global Non-Opioid Patch Sales Volume Share by Application (2021-2032)
- 5.3 Global Non-Opioid Patch Sales Value by Application
- 5.3.1 Global Non-Opioid Patch Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Non-Opioid Patch Sales Value by Application (2021-2032)
- 5.3.3 Global Non-Opioid Patch Sales Value Share by Application (2021-2032)
6 Non-Opioid Patch Regional Sales and Value Analysis
- 6.1 Global Non-Opioid Patch Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Non-Opioid Patch Sales by Region (2021-2032)
- 6.2.1 Global Non-Opioid Patch Sales by Region: 2021-2026
- 6.2.2 Global Non-Opioid Patch Sales by Region (2027-2032)
- 6.3 Global Non-Opioid Patch Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Non-Opioid Patch Sales Value by Region (2021-2032)
- 6.4.1 Global Non-Opioid Patch Sales Value by Region: 2021-2026
- 6.4.2 Global Non-Opioid Patch Sales Value by Region (2027-2032)
- 6.5 Global Non-Opioid Patch Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Non-Opioid Patch Sales Value (2021-2032)
- 6.6.2 North America Non-Opioid Patch Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Non-Opioid Patch Sales Value (2021-2032)
- 6.7.2 Europe Non-Opioid Patch Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Non-Opioid Patch Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Non-Opioid Patch Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Non-Opioid Patch Sales Value (2021-2032)
- 6.9.2 South America Non-Opioid Patch Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Non-Opioid Patch Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Non-Opioid Patch Sales Value Share by Country, 2025 VS 2032
7 Non-Opioid Patch Country-level Sales and Value Analysis
- 7.1 Global Non-Opioid Patch Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Non-Opioid Patch Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Non-Opioid Patch Sales by Country (2021-2032)
- 7.3.1 Global Non-Opioid Patch Sales by Country (2021-2026)
- 7.3.2 Global Non-Opioid Patch Sales by Country (2027-2032)
- 7.4 Global Non-Opioid Patch Sales Value by Country (2021-2032)
- 7.4.1 Global Non-Opioid Patch Sales Value by Country (2021-2026)
- 7.4.2 Global Non-Opioid Patch Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.9.2 France Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.16.2 China Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.19.2 India Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Non-Opioid Patch Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Non-Opioid Patch Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Non-Opioid Patch Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 Teva Pharmaceutical Industries Ltd
- 8.1.1 Teva Pharmaceutical Industries Ltd Company Information
- 8.1.2 Teva Pharmaceutical Industries Ltd Business Overview
- 8.1.3 Teva Pharmaceutical Industries Ltd Non-Opioid Patch Sales, Value and Gross Margin (2021-2026)
- 8.1.4 Teva Pharmaceutical Industries Ltd Non-Opioid Patch Product Portfolio
- 8.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
- 8.2 Johnson and Johnson
- 8.2.1 Johnson and Johnson Company Information
- 8.2.2 Johnson and Johnson Business Overview
- 8.2.3 Johnson and Johnson Non-Opioid Patch Sales, Value and Gross Margin (2021-2026)
- 8.2.4 Johnson and Johnson Non-Opioid Patch Product Portfolio
- 8.2.5 Johnson and Johnson Recent Developments
- 8.3 Viatris Inc.
- 8.3.1 Viatris Inc. Company Information
- 8.3.2 Viatris Inc. Business Overview
- 8.3.3 Viatris Inc. Non-Opioid Patch Sales, Value and Gross Margin (2021-2026)
- 8.3.4 Viatris Inc. Non-Opioid Patch Product Portfolio
- 8.3.5 Viatris Inc. Recent Developments
- 8.4 Sorrento Therapeutics Inc.
- 8.4.1 Sorrento Therapeutics Inc. Company Information
- 8.4.2 Sorrento Therapeutics Inc. Business Overview
- 8.4.3 Sorrento Therapeutics Inc. Non-Opioid Patch Sales, Value and Gross Margin (2021-2026)
- 8.4.4 Sorrento Therapeutics Inc. Non-Opioid Patch Product Portfolio
- 8.4.5 Sorrento Therapeutics Inc. Recent Developments
- 8.5 Purdue Pharma L.P.
- 8.5.1 Purdue Pharma L.P. Company Information
- 8.5.2 Purdue Pharma L.P. Business Overview
- 8.5.3 Purdue Pharma L.P. Non-Opioid Patch Sales, Value and Gross Margin (2021-2026)
- 8.5.4 Purdue Pharma L.P. Non-Opioid Patch Product Portfolio
- 8.5.5 Purdue Pharma L.P. Recent Developments
- 8.6 NEXGEL Advanced Hydrogel Solutions
- 8.6.1 NEXGEL Advanced Hydrogel Solutions Company Information
- 8.6.2 NEXGEL Advanced Hydrogel Solutions Business Overview
- 8.6.3 NEXGEL Advanced Hydrogel Solutions Non-Opioid Patch Sales, Value and Gross Margin (2021-2026)
- 8.6.4 NEXGEL Advanced Hydrogel Solutions Non-Opioid Patch Product Portfolio
- 8.6.5 NEXGEL Advanced Hydrogel Solutions Recent Developments
- 8.7 Hisamitsu Pharmaceutical Co.,Inc.
- 8.7.1 Hisamitsu Pharmaceutical Co.,Inc. Company Information
- 8.7.2 Hisamitsu Pharmaceutical Co.,Inc. Business Overview
- 8.7.3 Hisamitsu Pharmaceutical Co.,Inc. Non-Opioid Patch Sales, Value and Gross Margin (2021-2026)
- 8.7.4 Hisamitsu Pharmaceutical Co.,Inc. Non-Opioid Patch Product Portfolio
- 8.7.5 Hisamitsu Pharmaceutical Co.,Inc. Recent Developments
- 8.8 Grunenthal
- 8.8.1 Grunenthal Company Information
- 8.8.2 Grunenthal Business Overview
- 8.8.3 Grunenthal Non-Opioid Patch Sales, Value and Gross Margin (2021-2026)
- 8.8.4 Grunenthal Non-Opioid Patch Product Portfolio
- 8.8.5 Grunenthal Recent Developments
- 8.9 Endo International plc.
- 8.9.1 Endo International plc. Company Information
- 8.9.2 Endo International plc. Business Overview
- 8.9.3 Endo International plc. Non-Opioid Patch Sales, Value and Gross Margin (2021-2026)
- 8.9.4 Endo International plc. Non-Opioid Patch Product Portfolio
- 8.9.5 Endo International plc. Recent Developments
- 8.10 Amneal Pharmaceuticals LLC
- 8.10.1 Amneal Pharmaceuticals LLC Company Information
- 8.10.2 Amneal Pharmaceuticals LLC Business Overview
- 8.10.3 Amneal Pharmaceuticals LLC Non-Opioid Patch Sales, Value and Gross Margin (2021-2026)
- 8.10.4 Amneal Pharmaceuticals LLC Non-Opioid Patch Product Portfolio
- 8.10.5 Amneal Pharmaceuticals LLC Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Non-Opioid Patch Value Chain Analysis
- 9.1.1 Non-Opioid Patch Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Non-Opioid Patch Sales Mode & Process
- 9.2 Non-Opioid Patch Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Non-Opioid Patch Distributors
- 9.2.3 Non-Opioid Patch Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst